Ropanicant (SUVN-911) is an investigational new drug under development by Suven Life Sciences Ltd for the treatment of major depressive disorder (MDD) and other neurological conditions. It acts as an antagonist of the α4β2 nicotinic acetylcholine receptor (nAChR), a target involved in mood regulation and cognitive function.
Ropanicant (SUVN-911) is an investigational new drug under development by Suven Life Sciences Ltd for the treatment of major depressive disorder (MDD) and other neurological conditions. It acts as an antagonist of the α4β2 nicotinic acetylcholine receptor (nAChR), a target involved in mood regulation and cognitive function.
Source: Wikipedia "Ropanicant" · CC BY-SA 4.0
Share this article: X · Bluesky